Bio-Techne Corporation

$19.00

Want a discount? Become a member by purchasing Annual Subscription!
SKU: TECH Category:

Description

Bio-Techne Corporation: A Tale Of Resilience Amid Economic Challenges!

 

Bio-Techne, amidst challenging macroeconomic conditions, reported an organic revenue decline of 2% for the second quarter of the fiscal year 2024. The healthcare company’s earnings were impacted by various headwinds including a cautious biopharma spending environment, a tougher macroeconomic climate in China, and lowered demand from OEM customers. Bio-Techne’s core portfolio, however, continued to drive the company’s long-term growth potential with a 7% average growth rate over the last decade. The portfolio consisting of over 6,000 proteins and more than 400,000 antibodies, served as the backbone of the company.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!